Method and system for finding molecular marker based on transcriptome time sequence dynamic change and gene function association

Abstract

The invention discloses a method and a system for finding a molecular marker based on transcriptome time sequence dynamic change and gene function association. The method comprises the steps of acquiring a target pathophysiological process and a dynamic time sequence transcriptome change which accords with the pathophysiological process through multi-time-sequence sampling and high-flux transcriptome sequencing technology on a sample; through gene function association analysis, evaluating an association strength between a different coexpression set and the target pathophysiological process gene set, thereby finding the robust reliable marker with pathophysiological meaning in omics data. According to the method, the internal association between time sequence association and omics indexes is sufficiently used; the marker finding process is supported and verified by different types of information, thereby realizing high robustness. Therefore relatively low requirement for data measuringprecision and method parameter optimizing requirement is realized. The personnel without abundant practice experience and analysis experience can effectively use the method and the system.

Description

technical field [0001] The present invention relates to the field of using omics technology to find biomarkers, including but not limited to the development of diagnostic reagents, and in particular, to a method and system for discovering molecular markers based on the dynamic changes of transcriptome time sequence and gene function correlation. Background technique [0002] An important part of basic medical research is to use molecular means to characterize the pathophysiological mechanism and find key genes. Key genes can be biomarkers for early warning, diagnosis, and prognosis of diseases, or targets for treatment of diseases. [0003] Markers are only correlated with disease states, while targets require that interventions on the basis of correlations can alter the pathophysiological process of the disease. Therefore, in a sense, the target is a subset of markers, which may be obtained from further screening of markers for genes that are causally related to pathophysi...

AI Technical Summary

Problems solved by technology

And if there are hints in the literature, and researchers do it again, the innovation of the markers discovered may be insufficient, lacking scientific value and economic value

On the other hand, if there is not enough preliminary literature support, the risk of verification is high, and the cost of finally obtaining the mark is high, making it difficult to obtain project approval or investment

Second, the work of characterizing a group of candidate key genes in a large number of samples requires a large amount of experiments and a long cycle. Different experimenters and different batches may introduce high measurement errors, resulting in inaccurate evaluation

Third, the relationship between the candidate key genes suggested on the basis of existing knowledge and the pathological process may not be close enough, resulting in defects in the sensitivity and specificity of the markers discovered, often requiring the combined use of multiple markers, and interpretation Complex, with limited clinical translational value

These relatively small but actually more important upstream genes, the changes of which are difficult to pass the significance test of multiple statistical correction

Images